Xiumei Huang

Title: Xiumei Huang: Innovator in Tumor-Selective Combination Therapy

Introduction

Xiumei Huang is a prominent inventor based in Dallas, TX (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of tumor-selective combination therapies. With a total of 2 patents, her work focuses on creating therapies that can selectively target various cancer cell types and conditions.

Latest Patents

Xiumei Huang's latest patents revolve around tumor-selective combination therapy. The therapies described in her patents can be selectively lethal toward a variety of different cancer cell types and conditions in a subject. These combination therapies are particularly useful for the management, treatment, control, or adjunct treatment of diseases where selective lethality is beneficial in chemotherapeutic therapy, especially in cases accompanied by elevated levels of NQO1.

Career Highlights

Throughout her career, Xiumei Huang has worked with esteemed institutions such as the University of Texas System and the University of Illinois. Her research has garnered attention for its potential to improve cancer treatment outcomes and enhance the effectiveness of existing therapies.

Collaborations

Xiumei Huang has collaborated with notable professionals in her field, including Paul Joseph Hergenrother and David A Boothman. These collaborations have contributed to the advancement of her research and the development of innovative therapeutic strategies.

Conclusion

Xiumei Huang is a trailblazer in the realm of cancer therapy, with her innovative approaches promising to change the landscape of treatment for various cancer types. Her work exemplifies the impact of dedicated research and collaboration in the fight against cancer.